This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
JETREA®slowly continues to gain acceptance with the US retina community.
Company increasing US medical education efforts: increasing number of US-based Medical Science Liaison managers to 12.
US Organizational update: Dr Keith Steward appointed Head of US Business Operations.
Benefits of JETREA®, particularly in early stage patients, confirmed by positive reimbursement guidance from both the GB-A in Germany and NICE in the UK.
Alcon delivers important milestones with JETREA®in Rest of the World: Product approved in Canada, important clinical bridging study initiated in Japan, other multiple submissions are ongoing and planned.
Continued focus on diabetic eye diseases: Prevention of Proliferative Diabetic Retinopathy (PDR) is nextJETREA®target indication.
On September 30, 2013, the Company's cash position is Euro 183 Million, from Euro 193.6 Million on June 30, 2013.
ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, today issued a business update for the period ending
30 September, 2013.
ThromboGenics has developed JETREA
®, the first and only pharmacological treatment indicated for an important sight-threatening condition, symptomatic vitreomacular adhesion (VMA)/ vitreomacular traction (VMT) in the US and
Europe respectively. VMT/ symptomatic VMA is a progressive, sight-threatening condition that may lead to visual distortion, decreased visual acuity and central blindness.
mid-January 2013, the Company launched JETREA
® in the US through its own commercial organization.
April 2013, its partner Alcon launched JETREA
Europe after it was approved by the European Commission in March. In
Europe the drug is now available in the UK,
Sweden. First patients were also treated in
the Netherlands. ThromboGenics received €90 million in milestone payments from Alcon for the EU approval and first European sale of JETREA
In October, G-BA, the highest German decision-making body responsible for determining the health care services which will be reimbursed for over 70 million publicly insured persons in
Germany, confirmed the exceptional benefit appraisal JETREA
® received from IQWiG. G-BA concluded in its value assessment of JETREA
® that JETREA
® demonstrates significant therapeutic benefits for patients suffering from mild and moderate symptoms of VMT when compared with watchful waiting.
In October, UK's National Institute for Health and Care Excellence (NICE) final guidance has recommended that JETREA
® (ocriplasmin) should be reimbursed within the National Health Service (NHS) in
Wales as an option for treating VMT patients.
The NICE final guidance highlighted metamorphopsia as a 'severe and distressing' symptom, with its impact on the patient being comparable to a loss of two lines in visual acuity. In its final ruling, NICE has recommended reimbursing JETREA
® when used to treat patients suffering from metamorphopsia, one of the early signs of VMT.
In RoW, JETREA
® was approved in
Canada in August, for the treatment of symptomatic vitreomacular adhesion. This was the first approval of this innovative drug in a market outside the US and
Japan, Alcon has started its first clinical study with JETREA
®. This clinical bridging study is recruiting patients with symptomatic VMA/VMT including those associated with macular hole. The study is an important step in potentially gaining regulatory approval for ocriplasmin in
Japan, the world's second largest pharmaceutical market.
Dr Patrik De Haes, CEO of ThromboGenics comments:
"We are continuing to work to drive the adoption of this novel treatment option in patients with symptomatic VMA/VMT. Our medical education efforts are focused onchanging a treatment paradigm for early stage patients who usually undergo a period of watchful waiting prior to surgery. We are increasing the number of MSLs in theUSso we are better placed to highlight to retinaphysicians the multiple benefits of treating mild to moderate patients early."It is clear that these expanded educational efforts along with the provision of reimbursement and medical information support will require more time before they lead to a significant uptick inJETREA®'s prescribing. However, given the positive outcomes we have seen in a number ofJETREA®excellence centers across the US, we remain confident of generating a higher level of sales with this innovative new drug."In Europe, with our partner Alcon, we are encouraged by the very positive final guidance from the G-BA in Germany and NICE in the UK. Particularly important is that both of these rulings highlight the significant value of usingJETREA®for the treatment of patients with early symptoms. We are looking forward to further launches ofJETREA®across the EU during the next twelve months.Outside Europe, Alcon is continuing to make good progress withJETREA®, having recently received approval for the drug in Canada and having started an important clinical bridging study in Japan. This study is a key step in potentially gaining approval forJETREA®in the world's second largest pharmaceutical market."
For the full report please visit
® (ocriplasmin) is a truncated form of human plasmin. In the US, JETREA
® is indicated for the treatment of symptomatic VMA. In
® is indicated for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter ≤ 400 microns. JETREA
® is a selective proteolytic enzyme that cleaves fibronectin, laminin and collagen, three major components of the vitreoretinal interface that play an important role in vitreomacular adhesion.
® has been evaluated in two multi-center, randomized, double-masked Phase III trials conducted in the U.S. and
Europe involving 652 patients with vitreomacular adhesion. Both studies met the primary endpoint of resolution of VMA at day 28.
®'s Phase III program found that 26.5% of patients treated with ocriplasmin saw resolution of VMA, compared with 10.1% of patients receiving placebo (p<0.01).
The phase III program also showed that JETREA
® was generally well tolerated. Any adverse reactions were ocular. The most commonly reported were vitreous floaters, eye pain and photopsia, as well as conjunctival haemorrhage resulting from the injection procedure. Most of the adverse reactions occurred within the first week after the injection. The majority of these reactions was non-serious, mild in intensity and resolved within 2 to 3 weeks.